SARS-CoV2

[키워드] 30-Day mortality abnormality absolute neutrophil count active cancer advanced age age anti-CD20 therapy anti-CD20 treatment antibody Antibody test baseline board Cancer CD20 clinical clinical information Clinical outcome CLL cohort study conducted continuous variable contributing to cough COVID-19 COVID-19 diagnosis COVID-19 infection COVID-19 PCR test COVID-19 related mortality CRP current death demographic determine diabete diabetes Diagnosis died distribution DLBCL download Electronic health record equity ferritin Fever figure funding higher risk hypertension IgG antibody immune Immunity Impact indolent Infection Infinity IQR Kaplan-Meier method Kite Lymphocyte count lymphoma male Mann-Whitney marker mechanical ventilation median median age median time multicenter naïve number of comorbidities Observational cohort study Other outcome parameter Patient patients patients required hospitalization patients treated patients with SARS-CoV-2 Pearson performance status presenting symptom receive Regional repeated reported required retrospective risk Sample size SARS-CoV2 Seattle seronegative seropositive Shortness of breath shown significantly lower significantly more speaker subtype survival T cell tested the median therapy treated treated patient Treatment university variable variables viral shedding was obtained while with COVID-19
[DOI] 10.1182/blood-2020-141871 [Article Type] Conference abstract